EA201992460A1 - Антитела-агонисты btla и их применение - Google Patents

Антитела-агонисты btla и их применение

Info

Publication number
EA201992460A1
EA201992460A1 EA201992460A EA201992460A EA201992460A1 EA 201992460 A1 EA201992460 A1 EA 201992460A1 EA 201992460 A EA201992460 A EA 201992460A EA 201992460 A EA201992460 A EA 201992460A EA 201992460 A1 EA201992460 A1 EA 201992460A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
btla antibody
antibody antibodies
antibodies
btla
Prior art date
Application number
EA201992460A
Other languages
English (en)
Inventor
Шейн Круммен Атвелл
Виктор Х. Обунгу
Эндрю Чарльз Вендел
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201992460A1 publication Critical patent/EA201992460A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Предлагаются антитела, которые связывают BTLA, и способы их применения, причем указанные антитела пригодны в качестве агентов для лечения состояний, связанных с аутоиммунными заболеваниями, включая лечение волчанки.
EA201992460A 2017-05-19 2018-05-11 Антитела-агонисты btla и их применение EA201992460A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
PCT/US2018/032218 WO2018213113A1 (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA201992460A1 true EA201992460A1 (ru) 2020-03-18

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992460A EA201992460A1 (ru) 2017-05-19 2018-05-11 Антитела-агонисты btla и их применение

Country Status (25)

Country Link
US (2) US10604573B2 (ru)
EP (1) EP3625257A1 (ru)
JP (2) JP6790304B2 (ru)
KR (3) KR20210106033A (ru)
CN (3) CN117402244A (ru)
AR (1) AR111752A1 (ru)
AU (2) AU2018269585B2 (ru)
BR (1) BR112019021547A2 (ru)
CA (2) CA3184628A1 (ru)
CL (1) CL2019003215A1 (ru)
CO (1) CO2019012756A2 (ru)
CR (1) CR20190521A (ru)
DO (1) DOP2019000293A (ru)
EA (1) EA201992460A1 (ru)
EC (1) ECSP19082184A (ru)
JO (1) JOP20190261A1 (ru)
MA (1) MA49133A (ru)
MX (1) MX2019013604A (ru)
MY (1) MY197425A (ru)
NZ (1) NZ758360A (ru)
PE (1) PE20191843A1 (ru)
PH (1) PH12019502575A1 (ru)
TW (4) TWI677504B (ru)
WO (1) WO2018213113A1 (ru)
ZA (1) ZA201906954B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
AU2020368369A1 (en) 2019-10-15 2022-05-12 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
KR20230096024A (ko) * 2020-10-23 2023-06-29 아납티스바이오, 아이엔씨. B 및 t 림프구 약화인자 (btla) 조절제 및 이의 사용 방법
WO2023143565A1 (en) * 2022-01-29 2023-08-03 Hifibio (Hk) Limited Anti-btla antibodies and uses thereof in treating cancer
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
CA2503125C (en) * 2002-10-25 2013-04-30 Hilary Clark Novel composition and methods for the treatment of immune related diseases
EA200970477A1 (ru) * 2006-11-15 2009-12-30 Медарекс, Инк. Человеческие моноклональные антитела к btla и способы применения
EP2459594A1 (en) * 2009-07-31 2012-06-06 N.V. Organon Fully human antibodies to btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
US10005839B2 (en) * 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
WO2016176583A1 (en) * 2015-04-29 2016-11-03 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)

Also Published As

Publication number Publication date
KR20210106033A (ko) 2021-08-27
CL2019003215A1 (es) 2020-04-13
US10604573B2 (en) 2020-03-31
JP7072622B2 (ja) 2022-05-20
TW201946932A (zh) 2019-12-16
KR20190140969A (ko) 2019-12-20
PH12019502575A1 (en) 2020-07-13
JP2021019642A (ja) 2021-02-18
DOP2019000293A (es) 2019-12-15
CN110621699B (zh) 2023-10-31
WO2018213113A1 (en) 2018-11-22
JOP20190261A1 (ar) 2019-11-05
TWI747043B (zh) 2021-11-21
MA49133A (fr) 2020-03-25
CA3184628A1 (en) 2018-11-22
JP2020518288A (ja) 2020-06-25
CN110621699A (zh) 2019-12-27
JP6790304B2 (ja) 2020-11-25
KR102294051B1 (ko) 2021-08-27
AR111752A1 (es) 2019-08-14
EP3625257A1 (en) 2020-03-25
MX2019013604A (es) 2019-12-18
TW202233681A (zh) 2022-09-01
BR112019021547A2 (pt) 2020-05-12
ECSP19082184A (es) 2019-11-30
CR20190521A (es) 2020-01-06
TW202334237A (zh) 2023-09-01
US11396545B2 (en) 2022-07-26
CA3064518A1 (en) 2018-11-22
KR20220158847A (ko) 2022-12-01
NZ758360A (en) 2022-10-28
TWI677504B (zh) 2019-11-21
AU2021277743A1 (en) 2021-12-23
ZA201906954B (en) 2021-06-30
TW201904991A (zh) 2019-02-01
AU2018269585B2 (en) 2021-09-02
CN117402244A (zh) 2024-01-16
US20180334502A1 (en) 2018-11-22
CO2019012756A2 (es) 2020-01-17
TWI804044B (zh) 2023-06-01
AU2018269585A1 (en) 2019-10-31
MY197425A (en) 2023-06-16
CN117402245A (zh) 2024-01-16
PE20191843A1 (es) 2019-12-31
US20200239578A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA202092668A1 (ru) Антитела к ил-11
EA202092605A1 (ru) Антитела к ил-11ra
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA201492282A1 (ru) Антагонистические антигенсвязывающие белки к двум рецепторам и их применение
EA201991729A1 (ru) Антитела к tgf-бета и их применение
EA201992206A1 (ru) Моноклональное антитело к pd-l1
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA201501061A1 (ru) Антитела к igf-1r с элиминированной способностью связываться с fcrn и их применение для лечения сосудистых глазных заболеваний
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников